18F-FDG PET/CT对弥漫性大B细胞淋巴瘤的预后价值

doi:10.12117/jccmi.2020.05.011

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: The prognostic impact of total metabolic tumor volume(TMTV) measured on pretreatment 18F-FDG PET/CT was investigated in patients with diffuse large B-cell lymphoma(DLBCL). Methods: A total of 65 consecutive patients with DLBCL who received Rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy(R-CHOP) as first-line treatment and baseline FDG PET/CT were retrospectively evaluated. Receiver operating characteristic curve analysis was used to determine the optimal cut-off values for the metabolic parameters. The relationships between study variables and patient survival were tested using Cox regression analysis. Patient survival rates were derived from Kaplan-Meier curves and compared by using the log-rank test. Results: In patients with a low TMTV(<146 cm3), the 2-year progression free survival(PFS) rate was 43.1% and the overall survival(OS) rate was 45.3%, in contrast to 5.2% and 15.3%, respectively, in those with a high TMTV(≥146 cm3). Conclusions: TMTV of 18F-FDG PET/CT could be used as an important prognostic indicator for DLBCL.

Key words： Lymphoma, large-cell, diffuse Positron-emission tomography Tomography, spiral computed; Fluorodeoxyglucose F18

Received: 23 September 2019

PACS:	Ｒ733.1
	Ｒ817.4
	Ｒ814.42

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XIE Ting
	XU Kai
	HAN Cui-ping
	CHEN Qing-feng

Cite this article:

XIE Ting,XU Kai,HAN Cui-ping, et al. Prognostic value of metabolic tumor volume on baseline 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma[J]. JOURNAL OF CHINA MEDICAL IMAGING, 2020, 31(5): 350-353.

URL:

http://www.jccmi.com.cn/EN/10.12117/jccmi.2020.05.011 OR http://www.jccmi.com.cn/EN/Y2020/V31/I5/350

[1]Cottereau AS, Lanic H, Mareschal S, et al. Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma[J]. Clin Cancer Res, 2016, 22(15): 3801-3809.
[2]Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone[J]. J Clin Oncol, 2012, 30(28): 3452-3459.
[3]Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN Guidelines Insights: B-Cell Lymphomas, Version 32019[J]. J Natl Comprehensive Cancer Network, 2019, 17(6): 650-661.
[4]Duehrsen U, Andreas H, Stefan M, et al. Positron Emission Tomography(PET) Guided Therapy of Aggressive Lymphomas—a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results(PETAL Trial)[J]. Blood, 2014, 124(21): 391.
[5]Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 20[J]. Eur J Nucl Med Mol Imaging, 2015, 42(2): 328-354.
[6]Song MK, Yang DH, Lee GW, et al. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era[J]. Leukemia Res, 2016, 42(3): 1-6.
[7]Xie M, Wu K, Liu Y, et al. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants[J]. Med Oncol(Northwood, London, England), 2015, 32(1): 446.
[8]Meignan M, Sasanelli M, Casasnovas RO, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients[J]. Eur J Nucl Med Mol Imaging, 2014, 41(6): 1113-1122.
[9]Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index(NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era[J]. Blood, 2014, 123(6): 837-842.
[10]Mikhaeel NG, Smith D, Dumm JT, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL[J]. Eur J Nucl Med Mol Imaging, 2016, 43(7): 1209-1219.
[11]Sasanelli M, Meignan M, Haioun C, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma[J]. Eur J Nucl Med Mol Imaging, 2014, 41(11): 2017-2022.
[12]Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 20[J]. Eur J Nucl Med Mol Imaging, 2015, 42(2): 328-354.
[13]Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone[J]. J Clin Oncol, 2012, 30(28): 3452-3459.
[14]Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma[J]. Blood, 2013, 121(12): 2253-2263.